News details

image
MarketWatch / 05 March, 2024

Novo Nordisk says Ozempic reduced risk of kidney problems by 24% in patients with Type 2 diabetes

The company is planning to file for regulatory approval of a label expansion for Ozempic in the U.S. and European Union in 2024.

Leave a Reply

Your email address will not be published. Required fields are marked